Macrogenics (MGNX) Reports In-Line Q4 EPS

Macrogenics (NASDAQ: MGNX) reported Q4 EPS of ($0.15), in-line with the analyst estimate of ($0.15). Revenue for the quarter came in at $58.8 million versus the consensus estimate of $34.13 million.

For earnings history and earnings-related data on Macrogenics (MGNX) click here.

You May Also Be Interested In

• SanDisk upgraded at JPMorgan after investor day; shares climb
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c